» Articles » PMID: 28179437

Predictors of Mortality in Chronic Pulmonary Aspergillosis

Overview
Journal Eur Respir J
Specialty Pulmonary Medicine
Date 2017 Feb 10
PMID 28179437
Citations 68
Authors
Affiliations
Soon will be listed here.
Abstract

Chronic pulmonary aspergillosis (CPA) is a chronic progressive infection that destroys lung tissue in non-immunocompromised patients. Contemporary series suggest 50-85% 5-year mortality, with few prognostic factors identified.A cohort of 387 CPA patients referred to the UK's National Aspergillosis Centre from 1992 to June 2012 was studied until June 2015. The impact of objective and subjective variables including age, sex, previous pulmonary conditions, dyspnoea score, quality of life, serum albumin and C-reactive protein and radiological appearances were assessed using Kaplan-Meier curves, log rank tests and Cox proportional hazards modelling. In samples of patients, retrospective review of time from likely onset of CPA to referral and cause of death were also investigated.Survival was 86%, 62% and 47% at 1, 5 and 10 years, respectively. Increased mortality was associated with nontuberculous mycobacterial infection (hazard ratio 2.07, 95% CI 1.22-3.52; p<0.001) and chronic obstructive pulmonary disease (1.57, 1.05-2.36; p=0.029) as well as higher age (1.053, 1.03-1.07 per year; p<0.001), lower albumin (0.92, 0.87-0.96 per g·L), lower activity (1.021, 1.01-1.03 per point increase in St George's Respiratory Questionnaire activity domain; p<0.001) and having one, and especially, bilateral aspergillomas (p<0.001).Several factors impact on mortality of CPA, and can be evaluated as tools to assess CPA prognosis.

Citing Articles

The sulfur-related metabolic status of during infection reveals cytosolic serine hydroxymethyltransferase as a promising antifungal target.

Alharthi R, Sueiro-Olivares M, Storer I, Bin Shuraym H, Scott J, Al-Shidhani R Virulence. 2025; 16(1):2449075.

PMID: 39825596 PMC: 11749473. DOI: 10.1080/21505594.2024.2449075.


Antifungal Treatment for Japanese Patients with Chronic Pulmonary Aspergillosis.

Takazono T, Saito Y, Tashiro M, Yoshida M, Takeda K, Ide S Infect Dis Ther. 2024; 14(1):245-259.

PMID: 39722117 PMC: 11782703. DOI: 10.1007/s40121-024-01094-y.


Elevated mutation rates in multi-azole resistant Aspergillus fumigatus drive rapid evolution of antifungal resistance.

Bottery M, van Rhijn N, Chown H, Rhodes J, Celia-Sanchez B, Brewer M Nat Commun. 2024; 15(1):10654.

PMID: 39681549 PMC: 11649685. DOI: 10.1038/s41467-024-54568-5.


Successful treatment of chronic pulmonary aspergillosis in a patient with early pulmonary tuberculosis and COVID-19: a case report.

Bertucci A, Volpe-Chaves C, Mendo D, Andrade U, Lacerda M, Venturini J Multidiscip Respir Med. 2024; 19.

PMID: 39636397 PMC: 11661397. DOI: 10.5826/mrm.2024.989.


Mycobacterial lipoarabinomannan negatively interferes with macrophage responses to .

Gonzales-Huerta L, Williams T, Aljohani R, Robertson B, Evans C, Armstrong-James D bioRxiv. 2024; .

PMID: 39605324 PMC: 11601501. DOI: 10.1101/2024.11.18.623945.